Onco Actu du 2 juin 2015

Voir aussi le "Spécial ASCO" du jour

	3. Prévention
Let food be thy medicine and medicine be thy food? The obsessive worship of “medicinal foods” [Science-Based Medicine] This idée fixe that diet can fix everything even leads respectable doctors to write stories that are in some ways balanced but in other ways maddeningly credulous, like this story published last week in The New Republic by Dr. Sushrut Jangi, an Instructor in Medicine at Beth Israel Deaconess Medical Center, entitled “The Nutrition Gap.”
	3.1 Tabac
Smoking bans: How they vary around the world [BBC Newsbeat] Great Britain has some of the toughest smoking laws and penalties in the world. Many places have more exemptions with some countries having few laws at all.
	3.3 Prévention - Vaccins
Genticel Announces Positive Preclinical Proof of Concept Results of GTL002, its New Multivalent HPV Therapeutic Vaccine Candidate Based on Company’s Versatile Vaxiclase Platform [Genticel] With GTL001 and GTL002, Genticel is the first company that has established a staged pipeline of HPV therapeutic vaccines for the large female population burdened by this unmet medical need.
	4.2 Dép., diag. & prono. - Génome
Doctors aim for single test to detect risk of four cancers in women [The Guardian] The new test will look for DNA alterations, specific epigenetic changes and for the presence of certain bacteria, to give a personalised picture of the risk of developing one of the four cancers. These cancers represent 47% of all cancers in women.
	5. Traitements
Discovery could improve radiotherapy for wide range of cancers [Cancer Research UK] Cancer Research UK scientists have discovered how giving a class of drugs called AKT inhibitors in combination with radiotherapy might boost its effectiveness across a wide range of cancers, according to a study published in the Journal of Clinical Investigation.
​Leukemias With ALK Mutations Identified, May Respond to ALK Inhibitors [AACR] Mutations in the ALK gene were identified in the tumors of two leukemia patients, and laboratory studies indicated that leukemias harboring these mutations may respond to ALK inhibitors such as crizotinib and ceritinib, according to a study published in Cancer Research.
First-in-class HER3/EGFR Antibody Safe, With Antitumor Activity in Patients With Refractory Epithelial Cancers [AACR] Baselga and colleagues enrolled 66 patients at six sites in the United States and Spain: 30 patients to the dose-escalation study and 36 to the dose-expansion study.
	5.12 Immunothérapies
Want Immunotherapy Stock? One Guy's Index Could Become Tradable Fund [Xconomy] In March, independent investor Brad Loncar unveiled a homebrewed stock index, created to track the red-hot cancer immunotherapy field. If he gets his way, there will soon be a publicly traded fund to go with it.
	5.2 Pharma
At Exelixis, Morrissey Dreams Of Getting the Band Back Together [Xconomy] There’s even a scenario in which Exelixis—which in recent years has pushed most of its chips behind cabozantinib in prostate cancer (which failed) and other disease areas—could try to recapture its heyday, when it had a humming drug-discovery engine and a brimming pipeline.
Cancer breakthroughs trigger big pharma interest in drugs and deals [The Guardian] Since the start of 2014, there have been at least 44 corporate deals in the immuno-oncology market, according to Datamonitor, which tracks such transactions. One of the biggest was Pfizer’s $2.9bn collaboration with the French biotech company Cellectis.
Merck KGaA sees immunotherapy drug holding its own in cancer race [Reuters] The head of Merck KGaA's healthcare division said she expected its cancer drug avelumab, jointly developed with Pfizer, to be among the first two or three to market in a field of immunotherapy pharmaceuticals that harness the power of the immune system in a range of cancer types.
	5.2.1 Pharma - Partenariats
Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab [Amgen] First Trial to Combine These Investigational Immunotherapies for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases.
Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies [Merck] Studies to Evaluate the Combination of Dynavax’s SD-101 with Two Immunotherapies from Merck’s Pipeline, KEYTRUDA® (pembrolizumab) and MK-1966.
	5.3 Traitements - FDA, EMA,...
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Non-Small Cell Lung Cancer, and Grants Priority Review [Merck] KEYNOTE-001 Data Served as the Basis for U.S. FDA Filing and Breakthrough Therapy Designation in Advanced NSCLC Across Histologies.
	5.4 Traitements - Economie
NICE consults on draft guidance on olaparib for ovarian, fallopian tube and peritoneal cancer [NICE] The evidence provided shows that the price that the NHS is being asked to pay for olaparib is too high for the benefit it may provide to patients, so the preliminary guidance does not recommend it.
A disappointing decision over olaparib for ovarian cancer [Cancer Research UK] It’s particularly saddening to learn that, unlike patients in many other countries worldwide who already have, or will soon have access to olaparib, this drug is likely to be denied to patients in England.
Ovarian cancer patients denied innovative drug amid cost concerns [The Guardian] “Olaparib slows the progression of the disease for patients with some forms of ovarian cancer but the evidence that it can extend life is uncertain,” said Sir Andrew Dillon, the chief executive.
	6. Lutte contre les cancers
Spouses' Mood May Impact the Well-being of Cancer Survivors [AACR] Litzelman and colleagues used data from 910 cancer patients and their spouses from the Medical Expenditures Panel Survey. The researchers used statistical models to look at how each spouse’s quality of life or depressed mood at one time point was associated with his or her partner’s risk of depressed mood around 11 months later.
	6.1 Observation
Western Diet After Prostate Cancer Diagnosis Associated With Increased Risk of Death [AACR] “Our results suggest that the same dietary recommendations that are made to the general population primarily for the prevention of cardiovascular disease may also decrease the risk of dying from prostate cancer among men initially diagnosed with nonmetastatic disease,” Chavarro said.
Well: Breast-Fed Children at Lower Risk of Leukemia [NY Times] In the new study, published in JAMA Pediatrics, scientists found that children who were breast-fed for at least six months had a 19 percent lower risk of the disease compared with those who were not breast-fed at all or were breast-fed for shorter periods of time.
Western diet may reduce survival odds for prostate cancer [Reuters] An observational study like this can't prove that a Western diet causes prostate cancer. Still, said senior study author Dr. Jorge Chavarro in an email, “The strong link we found between greater adherence to the Western diet pattern and prostate-cancer specific death among these men – all of whom were free of metastasis at diagnosis – was very surprising.”